ESPE2015 Poster Category 3 Adrenals (47 abstracts)
aPediatric Endocrinology Department, Cerrahpasa Medical School, Istanbul, Turkey; bIntergen Genetics Center, Ankara, Turkey
Background: Corticosterone methyloxidase deficiency (CMOD) type 2 is an autosomal recessive disorder which presents with salt loss and failure to thrive in early childhood. We present three siblings with CMOD type 2 whose genetic analyses revealed a known c.1175T>C mutation (homozygous) and a novel c.788T>A mutation (homozygous) in CYP11B2 gene.
Case 1: The patient was admitted with salt loss and failure to thrive at the age of 6 months; had hyponatremia and hyperkalemia despite elevated renin and normal aldosterone levels. He was diagnosed as isolated aldosterone deficiency; salt and fludrocortisone treatment was started. At the age of 3 years, he had normal growth. He had high corticosterone, 18-OHcorticosterone and 18-OH corticosterone/ aldosterone ratio (78). Genetic analysis revealed c.1175T>C mutation(homozygous) and a novel c.788T>A mutation (homozygous) in CYP11B2 gene confirming the diagnosis of CMOD type 2. Parents with consanguineous marriage were heterozygous for both mutations.
Case 2: At the age of 2 years, brother of case 1 admitted with failure to thrive. According to medical records, he had suffered from salt loss at the age of 3 months. Although his electrolytes were normal his height and weight SDSs were −1.99 and −2.14 respectively. With fludrocortisone treatment his growth normalized. Genetic analysis revealed the same mutation his brother had.
Case 3: At the age of 3 months are admitted with poor weight gain, hyponatremia, mild hyperkalemia, increased renin and normal aldosterone levels. Fludrocortisone treatment resulted in adequate weight gain and normalized laboratory findings. Genetic analysis revealed the same mutation her brothers had.
Conclusion: Genetic analyses are beneficial for diagnosis of the patients and other relatives at the risk of salt loss and failure to thrive. The mutation c.1175T>C is known as responsible for reduction of enzyme activity; although novel mutation of c.788T>A probably affects the enzyme structure or function. Functional analyses will confirm loss of gene production.